LabGenius raises £35M Series B — Click to read more —
LabGenius raises £35M Series B — Click to read more —
Next-generation therapeutic antibodies.
The next wave of major scientific breakthroughs will be unlocked by technology platforms capable of combining the very best of human ingenuity and machine intelligence.
Our mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. To do this, we’re pioneering the development of a smart robotic platform (EVA™) that’s capable of designing, conducting and — critically — learning from its own experiments.
This approach will radically improve the drug discovery process, making the generation of advanced antibody therapeutics faster.
Featured in.
Platform technology.
Navigating antibody design space with conventional methods can be challenging.
Figure: Design space (referring to all possible designs in a highly multi-dimensional space).
Antibody discovery is hard because you have to navigate multiple design spaces simultaneously.
Conventional approaches rely on the sequential optimisation of different properties through rational design, which, whilst improving one property, can inadvertently worsen others.
These trade-offs can lead to costly failures or sub-optimal patient outcomes.
We intelligently navigate the design space using an iterative process called active learning.
LabGenius’ unique search capabilities come from the deep integration of disease-relevant cell-based assays, robotic automation and machine learning.
With this approach, for every design we experimentally evaluate, we’re able to predict the performance of up to 35x more.
Our approach increases the likelihood of finding high-performing antibodies, faster.
LabGenius’ pioneering technology platform uses an active learning method called Multi-Objective Bayesian Optimisation (MOBO) to enable the efficient co-optimisation of antibodies across multiple important properties.
In addition to being more efficient than conventional methods, our process is also designed to be free from human bias and yields high-performing antibodies with non-intuitive designs that are unlikely to have been found using rational design methods.
Platform applications.
We are initially deploying our platform technology to the rapid discovery and optimisation of novel therapeutic antibodies, for the treatment of cancer and inflammatory diseases.
We’ve used our platform to co-optimise mono- and multi-specific single domain antibodies for both biophysical and functional properties, including stability, potency and cell selectivity.
In parallel with partnered projects, the development of our internal pipeline is well underway, focusing on the discovery and optimisation of immunotherapeutics. Learn more about our immune cell engager lead optimisation capability by watching the video below.
Partnerships.
Test more
In <6 weeks, we can design, construct and experimentally test panels of >750 multispecific antibodies for both function (in complex cell-based assays) and developability.
Evaluate more
By combining our rapid data generation capability with state-of-the-art machine learning, we can evaluate the functional performance of >28,000 novel antibody designs in <12 weeks.
Find more
The tight integration of experimental and computational workflows into a closed-loop discovery engine enables the rapid and efficient exploration of large areas of antibody design space. By opening up the searchable design space, we can rapidly identify diverse panels of high-performing antibodies, many of which have non-intuitive designs.
To learn more get in touch at partnerships@labgeni.us.
Our investors.
Latest news.
News
Our team.
LabGenius’ highly multidisciplinary team brings together the best minds from the fields of computer science, robotic automation and synthetic biology.
We work by
our values.
Commitment to our company values has been core to LabGenius’ successes so far. They define the principles by which we work with one another, and our stakeholders, to drive the company forward. We’re incredibly proud of the culture we have cultivated, and our values continue to hold us accountable.
Feeling inspired?
UK Headquarters
G04 Cocoa Studios
The Biscuit Factory
100 Drummond Road
London
SE16 4DG
